Protagonist Therapeutics (PTGX) EBITDA (2015 - 2026)
Protagonist Therapeutics (PTGX) EBITDA from Jun 30, 2015 to Mar 31, 2026. The TTM Protagonist Therapeutics (PTGX) EBITDA is -$141M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Protagonist Therapeutics (PTGX) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 3 Years TTM | -0.98% |
| 5 Years TTM | +15.73% |
| 10 Years TTM | +26.31% |
| All Time TTM | +23.85% |
Annual EBITDA change of Protagonist Therapeutics (PTGX)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$3.24M | -97.93% |
| 2025 | -$157M | -161.83% |
| 2024 | $254M | -373.73% |
| 2023 | -$93M | -28.90% |
| 2022 | -$130M | +4.25% |
| 2021 | -$125M | +96.68% |
| 2020 | -$64M | -20.33% |
| 2019 | -$80M | +91.16% |
| 2018 | -$42M | +11.34% |
| 2017 | -$37M | +15.89% |
| 2016 | -$32M | +122.34% |
| 2015 | -$15M | +60.60% |
| 2014 | -$9.06M | N/A |
Comparison Protagonist Therapeutics (PTGX) five years EBITDA CAGR with competitors
Protagonist Therapeutics (PTGX) five years EBITDA CAGR is 15.73%.